{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 46,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Comparison of protein levels and tumor volume over time across multiple dosing regimens.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/36",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.28,
        "y": 0.55
      },
      "kind": "chart",
      "text": "GDF15 Protein Levels",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad75a4cf-327a-4cf3-aa19-d7f2655dd454",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "chart",
      "text": "p53 Protein Levels",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1d961a3-2016-4cca-99c9-50efd8445595",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "chart",
      "text": "MDM2 Protein Levels 1h post dosing",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26a10f57-29cd-4d03-af2b-d3b4f164b8a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "RS4;11 Tumor Volume",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "684ea4b8-23f5-4f87-95b7-8efbff18cc7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "chart",
      "text": "MV4;11 Tumor Volume",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ab5651c-a766-4a8d-8fdc-1c8ac7550da6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.82
      },
      "kind": "list",
      "text": "Sustained tumor regressions in RS4;11 (ALL) and MV4;11 (AML) CDX models after a single 3 mg/kg KT-253 dose; No efficacy observed with clinically relevant dosing regimen of SM (DS-3032)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26732346-e1a0-43f2-a532-9d9921f36cf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "list",
      "text": "Targeted proteomic analysis of RS4;11 tumors demonstrates robust degradation of MDM2 one hour post dosing and associated pathway activation biomarkers including p53 and GDF15",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6715a58c-a107-49bd-82f2-3c9b1c34b98d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.02
      },
      "kind": "title",
      "text": "KT-253 Potently Degrades MDM2 leading to Pathway Impact and Antitumor Activity Superior to SMI in ALL and AML Models",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3960d97f-fdec-4fe3-a2f4-61b5529ba3a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 46,
      "from": 21,
      "beatId": "5b777767-ae99-4f1a-ab2a-67ed14bef3b5",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, highlighting upcoming milestones and events.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}